– Starkes Q2 mit einem Gesamtumsatz von 361 Mio. USD, darunter 239 Mio. USD Produktumsatz – – Erwarteter Gesamtumsatz für das Gesamtjahr 2026 auf 1,18 bis 1,28 Mrd. USD angehoben, die Prognose für den Produktumsatz 2026 auf 850 bis 950 Mio. USD erhöht – – Sephience™ (sepiapterin) Q2-2026-Umsatz von 151 Mio. USD mit weiterhin breiter Akzeptanz und geografischer Expansion – – Starke Barposition v...
CONSHOHOCKEN, Pa., 23. Juli 2026 /PRNewswire/ -- Die führende Private‑Markets‑Investment‑Management‑Gesellschaft Hamilton Lane (Nasdaq: HLNE) gab bekannt, dass ihr Verwaltungsrat Michael Schmertzler mit Wirkung zum 22. Juli 2026 zum neuen unabhängigen Vorstandmitglied gewählt hat.
WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees.
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity – – Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 – WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate princi...
– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offering to include buyback of common stock – WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2031 (th...
PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.
– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, s...